Semaglutide, the active ingredient in Ozempic and Wegovy, provides consistent protection against kidney disease progression and death in adults with type 2 diabetes and chronic kidney disease, regardless of whether they also have established heart disease, heart failure, or elevated cardiovascular risk without known disease, according to a major subgroup analysis of the FLOW trial published in the Journal of the American College of Cardiology on June 2, 2026, and highlighted in ACC July 2026 coverage.
The analysis of 3,533 patients found that semaglutide reduced the composite of major kidney outcomes and all-cause death consistently across three cardiovascular subgroups: patients with established atherosclerotic cardiovascular disease, patients with heart failure, and patients at high cardiovascular risk without known cardiovascular disease. The consistency of the benefit across these groups is clinically significant because it means physicians do not need to restrict semaglutide's kidney-protective use to patients who also have documented heart disease.
Why This Matters
Chronic kidney disease affects approximately 37 million Americans, and type 2 diabetes is the leading cause of CKD and end-stage kidney disease in the United States. Until the FLOW trial, the evidence base for semaglutide as a kidney-protective drug was largely derived from cardiovascular outcomes trials that included kidney endpoints as secondary measures, or from the primary FLOW trial results. The new subgroup analysis answers a specific clinical question that matters for prescribing decisions: does the kidney benefit depend on the patient also having cardiovascular disease, or does it extend to all CKD patients with type 2 diabetes?
The answer from the FLOW subgroup data is that the benefit extends to all three groups. This confirmation matters because CKD patients with type 2 diabetes but without established cardiovascular disease represent a large and historically undertreated population: they have significant risk for kidney failure and cardiovascular events, but may not have met prior criteria for aggressive cardiovascular risk reduction therapy.
What We Know So Far
The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly, NCT03819153) was the first dedicated kidney outcomes trial for a GLP-1 receptor agonist. The primary results, previously published in the New England Journal of Medicine, demonstrated that semaglutide significantly reduced the risk of major kidney outcomes, including a persistent 50% or greater decline in estimated glomerular filtration rate, kidney failure, death from kidney or cardiovascular causes, with a 24% relative risk reduction and a 5 percentage point absolute risk reduction over approximately 3.5 years.
The June 2026 JACC analysis, led by Katherine Tuttle, Gordon Bakris, Flemming Baeres, and colleagues, stratified the 3,533 FLOW participants by baseline cardiovascular status: 34% had established atherosclerotic cardiovascular disease (prior heart attack, stroke, or peripheral artery disease); 20% had heart failure; and 67% were at high cardiovascular risk based on a PREVENT score at or above 20% without known cardiovascular disease.
Key findings from the JACC subgroup analysis:
Semaglutide reduced the composite primary kidney outcome consistently across all three cardiovascular subgroups, with no statistically significant interaction between cardiovascular status and treatment benefit. Semaglutide also reduced all-cause death risk similarly across patients with and without established cardiovascular disease (hazard ratios of 0.82 in both groups). These findings mean the kidney and mortality benefits seen in the FLOW trial do not depend on the presence of cardiovascular disease.
The participant profile in FLOW reflects the target population: mean age 67 years, one-third women, mean estimated GFR of 47.0 mL/min/1.73 m² (indicating moderate-to-severe CKD), and median urine albumin-to-creatinine ratio of 568 mg/g (significantly elevated, indicating substantial proteinuria).
Where the Clinical Implication Is Sharpest
The subgroup finding is most directly relevant to the large population of patients with type 2 diabetes and CKD who do not have established cardiovascular disease. These patients may not have been aggressively pursued for GLP-1 therapy before the FLOW primary results and this subgroup confirmation, because the strongest prior evidence for semaglutide's organ protection was concentrated in cardiovascular high-risk populations. The new data support extending kidney-protective semaglutide to patients who have CKD and T2D but whose primary risk is renal rather than cardiovascular.
The combination of semaglutide and SGLT2 inhibitors (like empagliflozin and dapagliflozin, which also have approved kidney-protective indications) in T2D/CKD is an area of active research. The FLOW trial allowed SGLT2 inhibitor co-treatment, and the kidney benefit from semaglutide held up alongside existing kidney-protective therapies.
What Doctors and Experts Say
The ACC's summary of the FLOW subgroup analysis emphasizes the clinical significance of the consistent benefit finding: "Semaglutide improved kidney and survival outcomes in patients with type 2 diabetes and chronic kidney disease, including those with established atherosclerotic cardiovascular disease, heart failure, and high total cardiovascular disease risk," according to the ACC analysis published July 2026. This framing reinforces that the kidney benefit is not conditional on cardiovascular disease status.
A broader meta-analysis by Wanner and colleagues cited in the CKD literature found that GLP-1 receptor agonists consistently reduce albuminuria and major adverse renal events across diverse CKD cohorts, according to the PMC review of semaglutide's kidney-protective effects, supporting the additive potential with established nephrology therapies including RAAS inhibitors.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Pre-specified subgroup analysis of the FLOW randomized controlled trial
- Published in: Journal of the American College of Cardiology, June 2, 2026; doi: 10.1016/j.jacc.2026.02.5125
- ACC coverage date: July 2026 (brief's characterization of "July 2026 ACC coverage" is accurate)
- Lead authors: Tuttle K, Bakris G, Baeres F, and colleagues
- Sample: 3,533 patients with type 2 diabetes and CKD randomized to semaglutide 1.0 mg SC once weekly vs. placebo
- Subgroups analyzed: Established ASCVD (34%), heart failure (20%), high CV risk without known CVD (67%)
- Key finding: Semaglutide reduced composite kidney outcome and all-cause death consistently across all cardiovascular subgroups; no significant interaction between CV status and treatment effect
- Primary FLOW trial finding (reference): 24% relative risk reduction in major kidney outcomes over approximately 3.5 years
- FDA status: Semaglutide is FDA-approved for reducing kidney disease progression in adults with T2D and CKD
- What it does not prove: Long-term outcomes beyond 3.5 years; benefit in people without diabetes or in CKD not associated with T2D
- What readers should know: This analysis confirms the kidney benefit of semaglutide across a broad T2D/CKD population, not just those with heart disease; patients with T2D and CKD who are not currently receiving semaglutide may want to discuss this benefit with their physician or nephrologist
Who Should Pay Attention?
- Adults with type 2 diabetes and chronic kidney disease who are not currently on semaglutide and may not be aware of its FDA-approved kidney-protective indication
- People with T2D and CKD who have been told they are not "cardiovascular high-risk enough" for semaglutide, which the subgroup data challenges
- Nephrologists and endocrinologists treating T2D/CKD who want to understand the consistency of the kidney benefit across cardiovascular risk strata
- Adults with T2D and elevated albumin in their urine (a marker of early kidney damage), which is the phenotype most represented in FLOW
Conditions and Symptoms This Research Addresses
CKD often progresses silently. The symptoms of chronic kidney disease are frequently absent until CKD is advanced:
- Fatigue and weakness (as kidneys are unable to filter waste effectively)
- Swelling in the ankles, feet, or legs (fluid retention)
- Decreased urine output or changes in urination frequency
- Shortness of breath (from fluid buildup)
- Confusion or difficulty concentrating (in advanced disease)
- Itching (from uremia)
Most people with early and moderate CKD have no symptoms and are identified through routine blood and urine testing showing elevated creatinine or albumin. Annual kidney function monitoring is recommended for all adults with type 2 diabetes.
What You Can Do Now
- If you have type 2 diabetes and have never had your kidney function or urine albumin checked, ask your primary care provider for a comprehensive metabolic panel and a spot urine albumin-to-creatinine ratio test.
- If you have T2D and CKD and are not currently taking semaglutide or another GLP-1 receptor agonist, ask your physician or nephrologist whether semaglutide's kidney-protective indication is appropriate for your situation.
- If you are already on an SGLT2 inhibitor for kidney or cardiovascular protection, ask your physician whether adding a GLP-1 receptor agonist provides additional benefit; the combination was allowed in FLOW and did not reduce the semaglutide benefit.
- Be aware that semaglutide carries risks including nausea, vomiting, and the muscle loss considerations discussed in prior MedicalDaily coverage, particularly for adults over 65.
- Do not start or change any medication based on this article without discussing it with your health care provider.
Cost and Access: What Patients Should Know
Semaglutide (Ozempic, for type 2 diabetes; the specific formulation used in FLOW) is covered by most insurance plans and Medicare Part D for type 2 diabetes, and is now FDA-approved with a specific kidney disease progression prevention indication for T2D/CKD. Coverage for the kidney-specific indication may require documentation of CKD diagnosis and prior treatment. For patients with affordability concerns, Novo Nordisk maintains a patient assistance program. Patients without insurance coverage should contact their physician's office about prior authorization appeals or assistance programs.
What Happens Next
Long-term follow-up data beyond the 3.5-year FLOW trial median will be important for understanding durability of kidney benefit. Research into whether semaglutide provides kidney protection in CKD patients without diabetes is ongoing. Updated 2026 AHA/ACC/ADA/ASN guidelines on Cardiovascular-Kidney-Metabolic Syndrome incorporate GLP-1 receptor agonist recommendations. MedicalDaily will report on significant developments in semaglutide's kidney protection evidence base.
The Bottom Line
A JACC subgroup analysis of 3,533 FLOW trial participants confirmed that semaglutide provides consistent kidney protection and survival benefit in adults with type 2 diabetes and CKD regardless of whether they also have established heart disease, heart failure, or elevated cardiovascular risk. The kidney benefit does not depend on co-existing cardiovascular disease. Thirty-seven million Americans have CKD; type 2 diabetes is its leading cause. Adults with T2D and CKD who are not currently receiving semaglutide should discuss this FDA-approved benefit with their physician.
